

```
=> s (FSH or follicle stimulating hormone) and (poloxamer 188 or pluronic f68 or
pluronic f 68)
      9  FILE CAPPLUS
      6  FILE DGENE
 33 FILES SEARCHED...
      9  FILE IFIPAT
      5  FILE TOXCENTER
      6  FILE USGENE
 459  FILE USPATFULL
102  FILE USPAT2
      9  FILE WPIDS
66 FILES SEARCHED...
      9  FILE WPINDEX
```

9 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX

L1 QUE (FSH OR FOLLICLE STIMULATING HORMONE) AND (POLOXAMER 188 OR PLURONIC F
68 OR PLURONIC F 68)

=> s 11
L2 14 L1

=> dup rem 12
PROCESSING COMPLETED FOR L2
L3 10 DUP REM L2 (4 DUPLICATES REMOVED)

=> d bib hit 1-
YOU HAVE REQUESTED DATA FROM 10 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 10 HCPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1
AN 2009:620826 HCPLUS
DN 150:547945
TI Pharmaceutical forms comprising a polymeric matrix for the release of
active compounds and absorption by mucosa
IN Lopez-Belmonte Encina, Ivan; Gutierrez Aduriz, Ibon
PA Laboratorios Farmaceuticos Rovi, S.A., Spain
SO PCT Int. Appl., 127pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2
 PATENT NO. KIND DATE APPLICATION NO. DATE
 ----- ----- ----- -----
PI WO 2009063021 A1 20090522 WO 2008-EP65499 20081113
 W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
 CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
 FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
 KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
 TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW,

AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 EP 2060253 A1 20090520 EP 2007-380319 20071114
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
 AL, BA, HR, MK, RS
 PRAI EP 2007-380319 A 20071114
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT
 IT 50-56-6, Oxytocin, biological studies 70-51-9, Desferrioxamine
 77-89-4, Acetyltriethyl citrate 363-24-6, Prostaglandin E2 492-62-6,
 α -D-Glucopyranose 1404-04-2, Neomycin 1404-90-6, Vancomycin
 3416-24-8, Glucosamine 9002-60-2, Adrenocorticotropin, biological
 studies 9002-64-6, Parathyroid hormone 9002-68-0, Follicle-
stimulating hormone 9004-10-8, Insulin, biological
 studies 9007-12-9, Calcitonin 9007-27-6, Chondroitin 9014-42-0,
 Thrombopoietin 9034-39-3, Growth-hormone releasing hormone 9034-40-6,
 Gonadotropin-releasing hormone 11000-17-2, Vasopressin 11041-12-6,
 Cholestryamine 11096-26-7, Erythropoietin 12629-01-5, Human growth
 hormone 15826-37-6, Cromolyn sodium 16110-51-3 35121-78-9, PG12
 37228-64-1, Glucocerebrosidase 51110-01-1, Somatostatin 59865-13-3,
 Cyclosporin 66419-50-9, Bovine growth hormone 75634-40-1, Dermatan
 85637-73-6, Atrial natriuretic factor 121181-53-1, Filgrastim
 691397-13-4, Pluronic F-68
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (comprns. comprising polymeric matrix including at least one cationic
 polymer for release and absorption by mucosa of hydrophilic agent)

L3 ANSWER 2 OF 10 HCPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2
 AN 2009:608389 HCPLUS
 DN 150:547892
 TI Pharmaceutical forms comprising a polymeric matrix for the release of
 active compounds and absorption by mucosa
 PA Laboratorios Farmaceuticos Rovi, S.A., Spain
 SO Eur. Pat. Appl., 71pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 2060253	A1	20090520	EP 2007-380319	20071114
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
WO 2009063021	A1	20090522	WO 2008-EP65499	20081113
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI EP 2007-380319 A 20071114

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 50-56-6, Oxytocin, biological studies 70-51-9, Desferrioxamine 77-89-4, Acetyltriethyl citrate 363-24-6, Prostaglandin E2 492-62-6, α -D-Glucopyranose 1404-04-2, Neomycin 1404-90-6, Vancomycin 3416-24-8, Glucosamine 9002-60-2, Adrenocorticotropin, biological studies 9002-64-6, Parathyroid hormone 9002-68-0, Follicle-stimulating hormone 9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin 9007-27-6, Chondroitin 9014-42-0, Thrombopoietin 9034-39-3, Growth-hormone releasing hormone 9034-40-6, Gonadotropin-releasing hormone 11000-17-2, Vasopressin 11041-12-6, Cholestryamine 11096-26-7, Erythropoietin 12629-01-5, Human growth hormone 15826-37-6, Cromolyn sodium 16110-51-3 35121-78-9, PGI2 37228-64-1, Glucocerebrosidase 51110-01-1, Somatostatin 59865-13-3, Cyclosporin 66419-50-9, Bovine growth hormone 75634-40-1, Dermatan 85637-73-6, Atrial natriuretic factor 121181-53-1, Filgrastim 691397-13-4, Pluronic F68
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comps. comprising polymeric matrix including at least one cationic polymer for release and absorption by mucosa of hydrophilic agent)

L3 ANSWER 3 OF 10 HCPLUS COPYRIGHT 2009 ACS on STN

AN 2007:329719 HCPLUS
DN 146:344763

TI Method for the quantitative determination of poloxamers

IN Rossi, Mara

PA Ares Trading S. A., Switz.

SO PCT Int. Appl., 29pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007031566	A1	20070322	WO 2006-EP66383	20060914
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU	2006290662	A1	20070322	AU 2006-290662	20060914
CA	2612613	A1	20070322	CA 2006-2612613	20060914
EP	1951395	A1	20080806	EP 2006-793534	20060914
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP	2009508132	T	20090226	JP 2008-530539	20060914
ZA	200800253	A	20090527	ZA 2008-253	20060914
IN	2007DN10026	A	20080620	IN 2007-DN10026	20071224
KR	2008043301	A	20080516	KR 2008-702042	20080125
CN	101262918	A	20080910	CN 2006-80033079	20080310
MX	2008003530	A	20080411	MX 2008-3530	20080313

US 20080190179	A1	20080814	US 2008-66799	20080313
NO 2008001794	A	20080414	NO 2008-1794	20080411
PRAI EP 2005-108439		20050914		
US 2005-717642P	P	20050916		
WO 2006-EP66383	W	20060914		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The invention relates to the anal. determination of poloxamers in a liquid protein

sample. Thus, **Poloxamer 188** concentration was analyzed in a sample of the com. available liquid hFSH formulation Gonad-F RFF Pen after 18 mo of storage at room temperature. The stability of the liquid formulation in

respect of **Poloxamer 188** was to be assessed. The **Poloxamer 188** concentration at the moment of preparation was about 100 mcg/mL.

IT 9002-61-3, Ovitrelle 9002-67-9, Luteinizing hormone 9002-68-0,

Follicle-stimulating hormone 9002-71-5,

Thyrotropin 9002-72-6, Somatotropin 106392-12-5, Poloxamer 660415-35-0, Serostim

RL: ANT (Analyte); ANST (Analytical study)

(method for quant. determination of poloxamers)

L3 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 3
 AN 2005:238432 HCAPLUS

DN 142:303641

TI Compositions capable of facilitating penetration across a biological barrier

IN Ben-Sasson, Shmuel A.; Cohen, Einat

PA Israel

SO U.S. Pat. Appl. Publ., 12 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20050058702	A1	20050317	US 2003-664989	20030917
US 20050136103	A1	20050623	US 2004-942300	20040916
AU 2004317954	A1	20051013	AU 2004-317954	20040917
CA 2539043	A1	20051013	CA 2004-2539043	20040917
WO 2005094785	A2	20051013	WO 2004-IB4452	20040917
WO 2005094785	A3	20060323		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1670500	A2	20060621	EP 2004-821561	20040917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

JP 2007523050	T	20070816	JP 2006-526736	20040917
US 20070172517	A1	20070726	US 2006-572249	20061213
US 20070275055	A1	20071129	US 2007-879374	20070716
PRAI US 2003-503615P	P	20030917		
US 2003-664989	A2	20030917		
US 2003-665184	A2	20030917		
WO 2004-IB4452	W	20040917		
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
AB	This invention relates to novel pharmaceutical compns. for delivery of biol. active mols., such as polypeptides, drugs and other therapeutic agents, across various biol. barriers mixing one or more effectors (anionic impermeable mols.) with a counter ion to the effector (a liquid forming cation). The invention also relates to methods of treating or preventing diseases by administering pharmaceutical compns. to affected subjects. For example, an ionic liquid forming cation was used to enable the translocation of insulin across an epithelial barrier. A composition containing recombinant human insulin and an ionic liquid forming cation, e.g., 1-butyl-3-methylimidazolium chloride, together with phytic acid, Pluronic F68 , aprotinin, Solutol HS-15, and N-acetylcysteine was administrated rectally or by injection into an intestinal loop of a test animal, e.g., a mouse. Blood glucose levels decrease in relation to the amount of insulin absorbed from the intestine into the bloodstream (i.e., in an amount that correlates to the amount of insulin absorbed). Thus, this drug delivery system can replace the need for insulin injections, thereby providing an efficient, safe and convenient route of administration for diabetes patients.			
IT	53-79-2, Puromycin 55-91-4, DFP 57-88-5D, Cholesterol, fatty acid esters 60-00-4, EDTA, biological studies 60-00-4D, EDTA, chitosan conjugates 64-17-5, Ethanol, biological studies 66-71-7, 1,10-Phenanthroline 67-63-0, Isopropanol, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 68-12-2, DMF, biological studies 71-23-8, Propanol, biological studies 71-36-3, n-Butanol, biological studies 75-65-0, tert-Butanol, biological studies 78-83-1, Isobutanol, biological studies 79-10-7D, Acrylic acid, derivs., polymers 83-86-3, Phytic acid 120-51-4, Benzyl benzoate 123-51-3, Isoamyl alcohol 329-98-6, PMSF 501-52-0, Benzenepropanoic acid 516-50-7D, Taurodeoxycholic acid, salts 621-71-6, Tricaprin 863-57-0, Sodium glycocholate 1405-87-4, Bacitracin 2364-87-6, TLCK 3858-83-1, p-Aminobenzamide 6303-21-5D, Phosphinic acid, dipeptide analogs 8001-27-2, Hirudin 9002-64-6, Parathyroid hormone 9002-67-9, Luteinizing hormone 9002-68-0, FSH 9002-72-6, Growth hormone 9004-10-8, Insulin, biological studies 9004-61-9, Hyaluronic acid 9005-49-6, Heparin, biological studies 9007-12-9, Calcitonin 9007-28-7, Chondroitin sulfate 9012-76-4D, Chitosan, EDTA conjugates 9034-40-6D, LHRH, analogs 9041-92-3, α 1-Antitrypsin 9050-30-0 9076-44-2, Chymostatin 9078-38-0, Soybean trypsin inhibitor 9087-70-1, Aprotinin 11096-26-7, Erythropoietin 24967-94-0, Dermatan sulfate 25322-68-3, Polyethylene glycol 30827-99-7, AEBSF 36357-77-4, Phosphoramidon 37213-49-3, α -Melanotropin 37330-34-0, Bowman-Birk inhibitor 37691-11-5, Antipain 42228-92-2, Acivicin 45470-32-4, 1,3-Dimethylimidazolium 51798-45-9, Elastatinal 51839-17-9 55123-66-5, Leupeptin 58970-76-6, Bestatin 59721-29-8, Camostat mesylate 61909-81-7, Solutol HS15 64111-53-1 65039-03-4, 1-Ethyl-3-methylimidazolium 65144-34-5 67655-94-1, Amastatin 70904-56-2, Kyotorphin 71933-13-6 76721-89-6, Thiorphan 80432-08-2, 1-Butyl-3-methylimidazolium 81733-79-1, Dalargin 83869-56-1, GM-CSF 85100-82-9, 1-Hexyl-3-methylimidazolium 88105-67-3 89703-10-6, FK-448 89750-14-1, Glucagon-like peptide 1 106096-93-9, BFGF 106392-12-5,			

Poloxamer 125867-77-8 128270-60-0, Hirulog 143011-72-7, G-CSF 157310-70-8, 1,2-Dimethyl-3-propylimidazolium 159519-65-0, T20 178631-03-3, 1-Methyl-3-octylimidazolium 313475-49-9 343952-32-9 847835-84-1D, sugar complexes

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compns. capable of facilitating penetration across biol. barrier comprising effectors and counter ions)

L3 ANSWER 5 OF 10 HCPLUS COPYRIGHT 2009 ACS on STN

AN 2007:233065 HCPLUS

DN 149:252477

TI Drug delivery system

IN Mehendre, Ratnakar; Khubchandani, Murlidhar; Phadtare, Ganesh Narayan

PA Alkem Laboratories Ltd., India

SO Indian Pat. Appl., 74pp.

CODEN: INXXBQ

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI IN 2003MU00317	A	20050204	IN 2003-MU317	20030331
PRAI IN 2003-MU317		20030331		

IT 50-00-0, Formaldehyde, biological studies 50-02-2, Dexamethasone
50-03-3, Hydrocortisone acetate 50-04-4, Cortisone acetate 50-23-7,
Hydrocortisone 50-24-8, Prednisolone 50-28-2,
Estra-1,3,5(10)-triene-3,17-diol (17 β)-, biological studies
50-48-6, Amitriptyline 50-49-7, Imipramine 50-53-3, Chlorpromazine,
biological studies 50-56-6, Oxytocin, biological studies 50-57-7,
Lypressin 50-70-4, Sorbitol, biological studies 50-78-2, Aspirin
50-99-7, Glucose, biological studies 52-86-8, Haloperidol 53-86-1,
Indomethacin 54-71-7, Pilocarpine hydrochloride 55-48-1, Atropine
sulfate 55-63-0, Nitroglycerin 55-91-4 56-81-5D, Glycerin,
palmitostearate 57-13-6, Urea, biological studies 57-48-7, Fructose,
biological studies 57-50-1, Sucrose, biological studies 57-63-6,
Ethynodiol diacetate 57-83-0, Progesterone, biological studies 58-18-4,
Methyltestosterone 58-25-3, Chlordiazepoxide 58-55-9, Theophylline,
biological studies 58-93-5, Hydrochlorothiazide 59-05-2, Methotrexate
59-66-5, Acetazolamide 59-92-7, Levodopa, biological studies 59-96-1,
Phenoxybenzamine 60-13-9, Amphetamine sulfate 61-68-7, Mefenamic acid
62-51-1, Methacholine chloride 63-42-3, Lactose 63-84-3 64-86-8,
Colchicine 68-22-4, Norethisterone 68-23-5, Norethynodrel 69-65-8,
Mannitol 71-81-8, Isopropamide iodide 72-33-3, Ethynodiol
3-methyl ether 73-48-3, Bendroflumethiazide 79-93-6, Phenaglycodol
80-74-0, Acetylulfosoxazole 82-66-6, Diphenadione 87-33-2, Isosorbide
dinitrate 87-69-4, Tartaric acid, biological studies 87-89-8, Inositol
94-20-2, Chloropropamide 100-42-5D, Styrene, polymers with
acrylonitrile, butadiene and polycarbonates 106-99-0D, Butadiene,
polymers with acrylonitrile, styrene and polycarbonates 107-13-1D,
Acrylonitrile, polymers with butadiene, styrene and polycarbonates
107-22-2, Glyoxal 111-30-8, Glutaraldehyde 114-07-8, Erythromycin
114-49-8, Scopolamine bromide 117-37-3, Anisindione 124-94-7,
Triamcinolone 298-59-9, Methyl phenidate hydrochloride 299-28-5,
Calcium gluconate 299-95-6, Isoproterenol sulfate 302-22-7,
Chlormadinone acetate 302-23-8, 17-Hydroxyprogesterone acetate
315-30-0, Allopurinol 378-44-9, Betamethasone 439-14-5, Diazepam
472-54-8, 19-Nor-progesterone 512-69-6, Raffinose 525-66-6,
Propranolol 530-78-9, Flufenamic acid 554-57-4, Methazolamide

555-30-6, Methyldopa 556-32-1, Magnesium succinate 590-63-6, Bethanechol chloride 614-39-1, Procainamide hydrochloride 826-39-1, Mecamylamine hydrochloride 834-28-6, Phenformin hydrochloride 972-02-1, Diphenidol 1104-22-9, Meclizine hydrochloride 1156-19-0, Tolazamide 1179-69-7, Thiethylperazine maleate 1257-78-9, Prochloroperazine edisylate 1319-82-0, Aminocaproic acid 1617-90-9, Vincamine 1707-14-8, Phenmetrazine hydrochloride 3416-26-0, Lidoflazine 4205-90-7, Clonidine 4310-35-4, Tridihexethyl chloride 4499-40-5, Theophylline choline 5051-62-7, Guanabenz 5104-49-4, Flurbiprofen 5905-52-2, Ferrous lactate 6533-00-2, Norgestrel 7297-25-8, Erythritol tetranitrate 7487-88-9, Magnesium sulfate, biological studies 7632-05-5, Sodium phosphate 7647-14-5, Sodium chloride, biological studies 7720-78-7, Ferrous sulfate 7757-82-6, Sodium sulfate, biological studies 7757-93-9, Dicalcium phosphate 7778-80-5, Potassium sulfate, biological studies 7786-30-3, Magnesium chloride, biological studies 9000-40-2, Carob gum 9001-98-3, Rennin 9002-18-0, Agar 9002-60-2, Corticotrophin, biological studies 9002-61-3, Chorionic gonadotropin 9002-62-4, Prolactin, biological studies 9002-64-6, Parathyroid hormone 9002-67-9, Luteinizing hormone 9002-68-0, **Follicle-stimulating hormone** 9002-71-5, Thyroid stimulating hormone 9002-88-4, Polyethylene 9002-89-5, Poly(vinyl alcohol) 9003-01-4, Acrylic acid polymer 9003-05-8 9003-07-0, Polypropylene 9003-11-6, Polyoxethylene-polyoxypolyene copolymer 9003-53-6, Polystyrene 9003-56-9, Acrylonitrile-butadiene-styrene terpolymer 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-34-6, Cellulose, biological studies 9004-34-6D, Cellulose, mono-, di-, triacylates, biological studies 9004-36-8, Cellulose acetate butyrate 9004-39-1, Cellulose acetate propionate 9004-54-0, Dextran, biological studies 9004-65-3, Methocel K100 M 9004-67-5, Methyl cellulose 9005-25-8D, Starch, graft copolymers 9007-12-9, Calcitonin 9007-16-3, Carbopol 934 9007-92-5, Glucagon, biological studies 9011-97-6, Pancreozymin 9012-09-3 9012-72-0D, Polyglucan, diester crosslinked 9035-69-2 9063-38-1, Sodium starch glycolate 10377-48-7, Lithium sulfate 11000-17-2, Vasopressin 12687-37-5D, Benzamphetamine, hydrochloride salts 13563-60-5, Norgesterone 13655-52-2, Alprenolol 15686-71-2, Cephalexin 15687-27-1, Ibuprofen 16068-46-5, Potassium phosphate 16662-47-8, Gallopamid 17692-38-5, Fluprofen 20830-75-5, Digoxin 22071-15-4, Ketoprofen 22131-79-9 22204-53-1, Naproxen 23413-80-1, Aluminum aspirin 25087-26-7D, Methacrylic acid polymer, hydroxyalkyl derivs. 25322-68-3, PEG400 26171-23-3, Tolmetin 26838-52-8 26839-75-8, Timolol 28297-73-6, Methamphetamine sulfate 28476-72-4, Indene-maleic anhydride polymer 29122-68-7, Atenolol 29679-58-1, Fenoprofen 31842-01-0, Indoprofen 33369-31-2, Zomepirac 36330-85-5, Fenbufen 38194-50-2, Sulindac 38304-91-5, Minoxidil 39320-21-3, Cellulose trivalerate 39562-70-4, Nitrendipine 42399-41-7, Diltiazem 42540-40-9, Mandol 51110-01-1, Somatostatin 51481-61-9, Cimetidine 51854-14-9, Tetalol 53714-56-0, Leuprolide 54182-58-0, Sucralfate 55985-32-5, Nicardipine 57010-31-8, Tiapamil 59695-59-9, Cephalexin hydrochloride 62571-86-2, Captopril 63675-72-9, Nisoldipine 66085-59-4, Nimodipine 66357-35-5, Ranitidine 66419-50-9, Bovine somatotropin 67351-34-2, Cellulose tripalmitate 67351-36-4, Cellulose trilauroate 67382-71-2 69539-53-3, Entintidine 72509-76-3, Felodipine 75847-73-3, Enalapril 76420-72-9, Enalaprilat 76547-98-3, Lisinopril 76824-35-6, Famotidine 76963-41-2, Nizatidine 78415-72-2, Milrinone 79467-23-5, Mioflazine 87333-19-5, Ramipril 88021-18-5, Prochloroperazine maleate 88150-42-9, Amlodipine 126467-48-9, Porcine growth hormone 138931-81-4 144376-97-6 178357-89-6 193699-68-2

691397-13-4, **Poloxamer 188**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug delivery system)

L3 ANSWER 6 OF 10 TOXCENTER COPYRIGHT 2009 ACS on STN
AN 2007:337413 TOXCENTER
CP Copyright 2009 ACS
DN CA14911252477N
TI Drug delivery system
AU Mehendre, Ratnakar; Khubchandani, Murlidhar; Phadtare, Ganesh Narayan
CS ASSIGNEE: Alkem Laboratories Ltd.
PI IN 2003MU00317 A 4 Feb 2005
SO (2005) Indian Pat. Appl., 74pp.
CODEN: INXXBQ.
CY INDIA
DT Patent
FS CAPLUS
OS CAPLUS 2007:233065
LA English
ED Entered STN: 28 Jul 2009
Last Updated on STN: 28 Jul 2009
RN 9003-01-4Q (crosslinked)
9034-40-6 (Luteinizing hormone-releasing factor)
51803-78-2 (Nimesulide)
99300-78-4 (Venlafaxine hydrochloride)
50-00-0 (Formaldehyde)
50-02-2 (Dexamethasone)
50-03-3 (Hydrocortisone acetate)
50-04-4 (Cortisone acetate)
50-23-7 (Hydrocortisone)
50-24-8 (Prednisolone)
50-28-2 (Estra-1,3,5(10)-triene-3,17-diol (17 β)-)
50-48-6 (Amitriptyline)
50-49-7 (Imipramine)
50-53-3 (Chlorpromazine)
50-56-6 (Oxytocin)
50-57-7 (Lyppressin)
50-70-4 (Sorbitol)
50-78-2 (Aspirin)
50-99-7 (Glucose)
52-86-8 (Haloperidol)
53-86-1 (Indomethacin)
54-71-7 (Pilocarpine hydrochloride)
55-48-1 (Atropine sulfate)
55-63-0 (Nitroglycerin)
56-81-5Q (Glycerin, palmitostearate)
57-13-6 (Urea)
57-48-7 (Fructose)
57-50-1 (Sucrose)
57-63-6 (Ethynodiol dihydrogesterone)
57-83-0 (Progesterone)
58-18-4 (Methyltestosterone)
58-25-3 (Chlordiazepoxide)
58-55-9 (Theophylline)
58-93-5 (Hydrochlorothiazide)
59-05-2 (Methotrexate)
59-66-5 (Acetazolamide)
59-92-7 (Levodopa)

59-96-1 (Phenoxybenzamine)
60-13-9 (Amphetamine sulfate)
61-68-7 (Mefenamic acid)
62-51-1 (Methacholine chloride)
63-42-3 (Lactose)
64-86-8 (Colchicine)
68-22-4 (Norethisterone)
68-23-5 (Norethynodrel)
69-65-8 (Mannitol)
71-81-8 (Isopropamide iodide)
72-33-3 (Ethynodiol estradiol 3-methyl ether)
73-48-3 (Bendroflumethiazide)
79-93-6 (Phenaglycodol)
80-74-0 (Acetylsulfisoxazole)
82-66-6 (Diphenadiione)
87-33-2 (Isosorbide dinitrate)
87-69-4 (Tartaric acid)
87-89-8 (Inositol)
94-20-2 (Chloropropanide)
100-42-5Q (Styrene, polymers with acrylonitrile, butadiene and polycarbonates)
106-99-0Q (Butadiene, polymers with acrylonitrile, styrene and polycarbonates)
107-13-1Q (Acrylonitrile, polymers with butadiene, styrene and polycarbonates)
107-22-2 (Glyoxal)
111-30-8 (Glutaraldehyde)
114-07-8 (Erythromycin)
114-49-8 (Scopolamine bromide)
117-37-3 (Anisindione)
124-94-7 (Triamcinolone)
298-59-9 (Methyl phenidate hydrochloride)
299-28-5 (Calcium gluconate)
299-95-6 (Isoproterenol sulfate)
302-22-7 (Chlormadinone acetate)
302-23-8 (17-Hydroxyprogesterone acetate)
315-30-0 (Allopurinol)
378-44-9 (Betamethasone)
439-14-5 (Diazepam)
472-54-8 (19-Nor-progesterone)
512-69-6 (Raffinose)
525-66-6 (Propranolol)
530-78-9 (Flufenamic acid)
554-57-4 (Methazolamide)
555-30-6 (Methyldopa)
556-32-1 (Magnesium succinate)
590-63-6 (Bethanechol chloride)
614-39-1 (Procainamide hydrochloride)
826-39-1 (Mecamylamine hydrochloride)
834-28-6 (Phenformin hydrochloride)
972-02-1 (Diphenidol)
1104-22-9 (Meclizine hydrochloride)
1156-19-0 (Tolazamide)
1179-69-7 (Thiethylperazine maleate)
1257-78-9 (Prochloroperazine edisylate)
1319-82-0 (Aminocaproic acid)
1617-90-9 (Vincamine)
1707-14-8 (Phenmetrazine hydrochloride)

3416-26-0 (Lidoflazine)
4205-90-7 (Clonidine)
4310-35-4 (Tridihexethyl chloride)
4499-40-5 (Theophylline cholinate)
5051-62-7 (Guanabenz)
5104-49-4 (Flurbiprofen)
5905-52-2 (Ferrous lactate)
6533-00-2 (Norgestrel)
7297-25-8 (Erythrityl tetranitrate)
7487-88-9 (Magnesium sulfate)
7632-05-5 (Sodium phosphate)
7647-14-5 (Sodium chloride)
7720-78-7 (Ferrous sulfate)
7757-82-6 (Sodium sulfate)
7757-93-9 (Dicalcium phosphate)
7778-80-5 (Potassium sulfate)
7786-30-3 (Magnesium chloride)
9000-40-2 (Carob gum)
9001-98-3 (Rennin)
9002-18-0 (Agar)
9002-60-2 (Corticotrophin)
9002-61-3 (Chorionic gonadotropin)
9002-62-4 (Prolactin)
9002-64-6 (Parathyroid hormone)
9002-67-9 (Luteinizing hormone)
9002-68-0 (**Follicle-stimulating hormone**)
9002-71-5 (Thyroid stimulating hormone)
9002-88-4 (Polyethylene)
9002-89-5 (Poly(vinyl alcohol))
9003-01-4 (Acrylic acid polymer)
9003-07-0 (Polypropylene)
9003-11-6 (Polyoxyethylene-polyoxypropylene copolymer)
9003-53-6 (Polystyrene)
9003-56-9 (Acrylonitrile-butadiene-styrene terpolymer)
9004-10-8 (Insulin)
9004-32-4 (Carboxymethylcellulose)
9004-34-6 (Cellulose)
9004-34-6Q (Cellulose, mono-, di-, triacylates)
9004-36-8 (Cellulose acetate butyrate)
9004-39-1 (Cellulose acetate propionate)
9004-54-0 (Dextran)
9004-65-3 (Methocel K100 M)
9004-67-5 (Methyl cellulose)
9005-25-8Q (Starch, graft copolymers)
9007-12-9 (Calcitonin)
9007-16-3 (Carbopol 934)
9007-92-5 (Glucagon)
9011-97-6 (Pancreozymin)
9012-72-0Q (Polyglucan, diester crosslinked)
9063-38-1 (Sodium starch glycolate)
10377-48-7 (Lithium sulfate)
11000-17-2 (Vasopressin)
12687-37-5Q (Benzamphetamine, hydrochloride salts)
13563-60-5 (Norgestrone)
13655-52-2 (Alprenolol)
15686-71-2 (Cephalexin)
15687-27-1 (Ibuprofen)
16068-46-5 (Potassium phosphate)

16662-47-8 (Gallopamil)
17692-38-5 (Fluprofen)
20830-75-5 (Digoxin)
22071-15-4 (Ketoprofen)
22204-53-1 (Naproxen)
23413-80-1 (Aluminum aspirin)
25087-26-70 (Methacrylic acid polymer, hydroxyalkyl derivs.)
25322-68-3 (PEG400)
26171-23-3 (Tolmetin)
26839-75-8 (Timolol)
28297-73-6 (Methamphetamine sulfate)
28476-72-4 (Indene-maleic anhydride polymer)
29122-68-7 (Atenolol)
29679-58-1 (Fenoprofen)
31842-01-0 (Indoprofen)
33369-31-2 (Zomepirac)
36330-85-5 (Fenbufen)
38194-50-2 (Sulindac)
38304-91-5 (Minoxidil)
39320-21-3 (Cellulose trivalerate)
39562-70-4 (Nitrendipine)
42399-41-7 (Diltiazem)
42540-40-9 (Mandol)
51110-01-1 (Somatostatin)
51481-61-9 (Cimetidine)
51854-14-9 (Tetalol)
53714-56-0 (Leuprolide)
54182-58-0 (Sucralfate)
55985-32-5 (Nicardipine)
57010-31-8 (Tiapamil)
59695-59-9 (Cephalexin hydrochloride)
62571-86-2 (Captopril)
63675-72-9 (Nisoldipine)
66085-59-4 (Nimodipine)
66357-35-5 (Ranitidine)
66419-50-9 (Bovine somatotropin)
67351-34-2 (Cellulose tripalmitate)
67351-36-4 (Cellulose triaurate)
69539-53-3 (Etintidine)
72509-76-3 (Felodipine)
75847-73-3 (Enalapril)
76420-72-9 (Enalaprilat)
76547-98-3 (Lisinopril)
76824-35-6 (Famotidine)
76963-41-2 (Nizatidine)
78415-72-2 (Milrinone)
79467-23-5 (Mioflazine)
87333-19-5 (Ramipril)
88021-18-5 (Prochloroperazine maleate)
88150-42-9 (Amlodipine)
126467-48-9 (Porcine growth hormone)
691397-13-4 (**Poloxamer 188**)
9002-72-6 (Growth hormone)
RN 55-91-4; 63-84-3; 9003-05-8; 9012-09-3; 9035-69-2; 22131-79-9; 26838-52-8;
67382-71-2; 138931-81-4; 144376-97-6; 178357-89-6; 193699-68-2

DN 141:162351
 TI Peptides capable of facilitating penetration across a biological barrier and their use in drug delivery
 IN Ben-Sasson, Shmuel A.; Cohen, Einat
 PA Chiasma, Inc., USA
 SO U.S. Pat. Appl. Publ., 54 pp., Cont.-in-part of Appl. No. PCT/03IB/00968.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040146549	A1	20040729	US 2003-665184	20030917
	US 7115707	B2	20061003		
	WO 2003066859	A2	20030814	WO 2003-IB968	20030207
	WO 2003066859	A3	20040513		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050136103	A1	20050623	US 2004-942300	20040916
	AU 2004317954	A1	20051013	AU 2004-317954	20040917
	CA 2539043	A1	20051013	CA 2004-2539043	20040917
	WO 2005094785	A2	20051013	WO 2004-IB4452	20040917
	WO 2005094785	A3	20060323		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1670500	A2	20060621	EP 2004-821561	20040917
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007523050	T	20070816	JP 2006-526736	20040917
	US 20060251713	A1	20061109	US 2006-489391	20060718
	US 20070172517	A1	20070726	US 2006-572249	20061213
PRAI	US 2002-355396P	P	20020207		
	WO 2003-IB968	A2	20030207		
	US 2003-503615P	P	20030917		
	US 2003-664989	A2	20030917		
	US 2003-665184	A2	20030917		
	WO 2004-IB4452	W	20040917		
OSC.G 4	THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)				
RE.CNT 42	THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD				
	ALL CITATIONS AVAILABLE IN THE RE FORMAT				
IT 516-50-7D, peptide conjugate	25322-68-3D, Polyethylene glycol, peptide				

conjugates 691397-13-4D, **Pluronic F-68**,

peptide conjugate

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(peptides capable of facilitating penetration across biol. barrier and their use in drug delivery)

IT 68-19-9D, Vitamin B12, conjugates with peptides 1403-66-3D, Gentamycin, fusion product 1404-04-2D, Neomycin, fusion product 8001-27-2D, Hirudin, analogs, fusion products 8001-27-2D, Hirudin, fusion product 9002-64-6, Parathyroid hormone 9002-67-9, Luteinizing hormone 9002-68-0, **Follicle-stimulating hormone**

9002-72-6D, Somatotropin, fusion products 9002-79-3D, MSH, fusion products 9004-10-8D, Insulin, fusion products 9004-61-9D, Hyaluronic acid, fusion products 9005-49-6D, Heparin sulfate, fusion products 9007-12-9, Calcitonin 9007-28-7D, Chondroitin sulfate, fusion products 9034-40-6D, Luteinizing hormone releasing hormone, analogs, fusion products 9041-92-3, α -Antitrypsin 11096-26-7D, Erythropoietin, fusion products 24967-94-0D, Dermatan sulfate, fusion products 32986-56-4D, Tobramycin, fusion product 37213-49-3D, α -Melanocyte-stimulating hormone, fusion products 37517-28-5D, Amikacin, fusion product 70904-56-2D, Kytorphin, fusion product 70904-56-2D, Kytorphin, fusion products 81733-79-1D, Dalargin, fusion product 81733-79-1D, Dalargin, fusion products 83869-56-1D, GM-CSF, fusion products 89750-14-1D, Glucagon-like peptide 1, fusion products 106096-93-9D, Basic fibroblast growth factor, fusion products 128270-60-0D, Hirulog, fusion product 162808-62-0D, Caspofungin, fusion products

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peptides capable of facilitating penetration across biol. barrier and their use in drug delivery)

L3 ANSWER 8 OF 10 HCPLUS COPYRIGHT 2009 ACS on STN
AN 2004:1037120 HCPLUS

DN 142:3043

TI Method of chromatographic analysis of a protein solution

IN Arpaia, Giuseppe; Berardi, Marco; Chavez, Enrico; Driebergen, Reinoud; Giartosio, Carlo Emanuele; Lepage, Pierre

PA Ares Trading S. A., Switz.

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004104025	A1	20041202	WO 2004-EP5401	20040518
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GD, GW, ML, MR, NE, SN, TD, TG				
AU	2004240748	A1	20041202	AU 2004-240748	20040518
CA	2522989	A1	20041202	CA 2004-2522989	20040518

EP 1625147	A1	20060215	EP 2004-733570	20040518
EP 1625147	B1	20080123		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007531871	T	20071108	JP 2006-529874	20040518
AT 384735	T	20080215	AT 2004-733570	20040518
ES 2297423	T3	20080501	ES 2004-733570	20040518
US 20070072303	A1	20070329	US 2005-556803	20051114
NO 2005006085	A	20051221	NO 2005-6085	20051221
PRAI EP 2003-101458	A	20030521		
WO 2004-EP5401	W	20040518		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 9002-68-0, *Follicle-stimulating hormone*
145258-61-3, Interferon β 1 (human fibroblast protein moiety)
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(method of chromatog. anal. of protein solution)
IT 127-09-3, Sodium acetate 106392-12-5, *Poloxamer-188*
RL: ARU (Analytical role, unclassified); ANST (Analytical study)
(method of chromatog. anal. of protein solution)

L3 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:857444 HCAPLUS

DN 141:337782

TI Liquid pharmaceutical formulations of *FSH* and LH together with a non-ionic surfactant

IN Samaritani, Fabrizio; Donati, Piergiorgio

PA Ares Trading S.A., Switz.

SO PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004087213	A1	20041014	WO 2004-EP50432	20040402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2004226666	A1	20041014	AU 2004-226666	20040402
AU 2004226666	B2	20090903		
CA 2518903	A1	20041014	CA 2004-2518903	20040402
EP 1610822	A1	20060104	EP 2004-725385	20040402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009532	A	20060418	BR 2004-9532	20040402
CN 1795012	A	20060628	CN 2004-80014504	20040402

JP 2006522072	T	20060928	JP 2006-505517	20040402
ZA 2005007287	A	20070328	ZA 2005-7287	20040402
NZ 542247	A	20080328	NZ 2004-542247	20040402
IN 2005DN04138	A	20070831	IN 2005-DN4138	20050514
NO 2005004982	A	20051026	NO 2005-4982	20051026
US 20060147480	A1	20060706	US 2006-551840	20060120
PRAI EP 2003-100882	A	20030402		
EP 2003-101543	A	20030527		
EP 2003-101828	A	20030620		
WO 2004-EP50432	A	20040402		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant

AB The invention relates to the field of pharmaceutical formulations of follicle-stimulating hormone (FSH), luteinising hormone (LH), and mixts. of FSH and luteinising hormone (LH), and to methods of producing such formulations. The invention provides a liquid or freeze-dried formulation of FSH, or LH, or FSH and LH comprising a surfactant selected from Pluronic F77, Pluronic F87, Pluronic F88 and Pluronic F68, an antibacterial, an antioxidant, excipients and an osmoticum. FSH formulations containing 150-1200 IU/mL that were stable in sealed vials at room temperature for up to two years were developed.

ST FSH liq nonionic surfactant Pluronic; LH liq nonionic surfactant Pluronic

IT Drug delivery systems
(freeze-dried; liquid pharmaceutical formulations of FSH and LH together with non-ionic surfactant)

IT Drug delivery systems
(injections, freeze-dried; liquid pharmaceutical formulations of FSH and LH together with non-ionic surfactant)

IT Drug delivery systems
(injections, i.m.; liquid pharmaceutical formulations of FSH and LH together with non-ionic surfactant)

IT Drug delivery systems
(injections, s.c.; liquid pharmaceutical formulations of FSH and LH together with non-ionic surfactant)

IT Antibacterial agents
(liquid pharmaceutical formulations of FSH and LH together with non-ionic surfactant)

IT Drug delivery systems
(liqs.; liquid pharmaceutical formulations of FSH and LH together with non-ionic surfactant)

IT Surfactants
(nonionic; liquid pharmaceutical formulations of FSH and LH together with non-ionic surfactant)

IT Buffers
(phosphate; liquid pharmaceutical formulations of FSH and LH together with non-ionic surfactant)

IT 63-68-3, L-Methionine, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as antioxidant; liquid pharmaceutical formulations of FSH and LH together with non-ionic surfactant)

IT 108-39-4, m-Cresol, biological studies 108-95-2, Phenol, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as bacteriostatic; liquid pharmaceutical formulations of FSH and LH together with non-ionic surfactant)

IT 57-50-1, Sucrose, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as osmotic; liquid pharmaceutical formulations of FSH and LH together with non-ionic surfactant)

IT 8049-76-1, Follicle-stimulating hormone,
 mixture with luteinizing hormone 9002-67-9, Luteinising hormone 9002-68-0, Follicle-stimulating hormone 691397-13-4, Pluronic F77
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (liquid pharmaceutical formulations of FSH and LH together with non-ionic surfactant)

IT 772073-02-6 772073-03-7 772073-04-8 772073-05-9 772073-06-0
 772073-07-1
 RL: PRP (Properties)
 (unclaimed protein sequence; liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant)

L3 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
 AN 1999:819473 HCAPLUS
 DN 132:61290

TI A method for in vitro maturation of human gametes
 IN Lindenberg, Svend; Mikkelsen, Anne Lis; Smith, Steven Dale; Bertheussen, Kjell

PA Medi-Cult A/S, Den.
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9967365	A1	19991229	WO 1999-DK345	19990622
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JE, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA	2335793	A1	19991229	CA 1999-2335793	19990622
EP	1088056	A1	20010404	EP 1999-926294	19990622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR	200003830	T2	20020121	TR 2000-3830	19990622
CN	1161615	C	20040811	CN 1999-809930	19990622
CN	1607391	A	20050420	CN 2004-10048994	19990622
AT	407363	T	20080915	AT 1999-926293	19990622
ES	2313785	T3	20090301	ES 1999-926293	19990622
NO	2000006545	A	20010221	NO 2000-6545	20001221
US	20010028878	A1	20011011	US 2000-746656	20001222
US	20020115211	A1	20020822	US 2000-746633	20001222
PRAI	DK 1998-885	A	19980622		
US	1998-90115P	P	19980622		
	WO 1999-DK345	W	19990622		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 9002-68-0, FSH

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(method for in vitro maturation of human gametes)

IT 57-88-5, Cholesterol, biological studies 64-17-5, Ethanol, biological
studies 64-19-7, Acetic acid, biological studies 77-92-9, biological
studies 139-33-3 141-43-5, biological studies 604-35-3, Cholesteryl
acetate 4431-00-9, Aurin tricarboxylic acid 6132-04-3 7446-08-4,
Selenium dioxide 7647-01-0, Hydrochloric acid, biological studies
7758-99-8, Copper sulfate pentahydrate 7784-26-1, Ammonium aluminum
sulfate dodecahydrate 7785-87-7, Manganese sulfate 7791-13-1
9002-61-3, Chorionic gonadotropin 9003-39-8, Polyvinyl pyrrolidone
13478-00-7, Nickel nitrate hexahydrate 13986-24-8, Zinc sulfate
hexahydrate 15708-42-6 106392-12-5, Pluronic F-

68 253141-25-2

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)

(method for in vitro maturation of human gametes)